CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Agents
  • Carcinoma, Renal Cell
  • Hypertension
  • Indoles
  • Kidney Neoplasms
  • Neutropenia
  • Pyrroles

abstract

  • We investigated the impact of demographic and pretreatment features on survival benefit and tumor response with nivolumab versus everolimus in advanced renal cell carcinoma (aRCC). Survival benefit and response were observed for multiple subgroups, supporting the use of nivolumab as a new standard of care across a broad range of patients with previously treated aRCC. The trial is registered on ClinicalTrials.gov as NCT01668784.

publication date

  • January 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1016/j.eururo.2017.02.010

PubMed ID

  • 28262413

Additional Document Info